Panel Discussion: Integrating Biomarkers Throughout the Trajectory of CNS Drug Discovery & Development to Guide Clinical Decisions

Time: 12:00 pm
day: Day 2 afternoon


  • Discussing & debating whether biopharma should strive to achieve disease modification or improvement in quality of life when developing therapies for Alzheimer’s
  • Exploring the impact of Aducanumab on international approval for neurodegenerative disease
  • Learning what steps you must take to tailor your drug development approach to meet regulatory standards